About us Contacts Drug interactions: 390 212
Drug search by name

Disopyramide and Zithromax (Azithromycin Oral Suspension)

Determining the interaction of Disopyramide and Zithromax (Azithromycin Oral Suspension) and the possibility of their joint administration.

Check result:
Disopyramide <> Zithromax (Azithromycin Oral Suspension)
Relevance: 20.05.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Talk to your doctor before using disopyramide together with azithromycin. Combining these medications can increase the risk of an irregular heart rhythm that is potentially life-threatening. In addition, disopyramide blood levels may be increased by medications like azithromycin, which may make you more likely to experience side effects such as dry mouth, abdominal pain, constipation, blurred vision, difficulty urinating, low blood sugar, low blood pressure, and slow heart rate. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or special monitoring by your doctor to safely use both medications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or fast or pounding heartbeats during treatment with disopyramide. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Disopyramide can cause dose-related prolongation of the QT interval. Coadministration with other agents that can prolong the QT interval such as macrolide antibiotics may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). Some macrolides such as clarithromycin, erythromycin, and troleandomycin are also potent inhibitors of CYP450 3A4 and may significantly inhibit the metabolism of disopyramide, which is thought to be a substrate of the isoenzyme. Hypoglycemic coma, QT prolongation, torsade de pointes, and ventricular fibrillation have been reported in patients treated with disopyramide following the addition of clarithromycin, sometimes in association with elevated serum levels of disopyramide. Similarly, there have been cases of polymorphic ventricular tachycardia including torsade de pointes in association with significantly prolonged QTc intervals and/or elevated disopyramide levels during concomitant administration of erythromycin, both intravenous and oral. Although azithromycin is not thought to be an inhibitor of CYP450 3A4, elevated disopyramide levels and ventricular tachycardia requiring cardioversion occurred in a patient receiving disopyramide after she started on azithromycin less than 2 weeks earlier.

MANAGEMENT: The concurrent use of disopyramide with other medications that can prolong the QT interval should generally be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if these agents are prescribed together, especially to patients with underlying risk factors. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.

References
  • "Product Information. Erythrocin Lactobionate (erythromycin)." Abbott Pharmaceutical, Abbott Park, IL.
  • Paar D, Terjung B, Sauerbruch T "Life-threatening interaction between clarithromycin and disopyramide." Lancet 349 (1997): 326-7
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T "Hypoglycemia induced by interaction between clarithromycin and disopyramide." Jpn Heart J 40 (1999): 91-6
  • "Product Information. Zithromax (azithromycin)." Pfizer US Pharmaceuticals, New York, NY.
  • Ragosta M, Weihl AC, Rosenfeld LE "Potentially fatal interaction between erythromycin and disopyramide." Am J Med 86 (1989): 465-6
  • Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K "Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia." Pacing Clin Electrophysiol 22(4 Pt 1) (1999): 672-4
  • "Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical, Abbott Park, IL.
  • Echizen H, Kawasaki H, Chiba K, Tani M, Ishizaki T "A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-n-dealkylation metabolism of disopyramide with human liver microsomes." J Pharmacol Exp Ther 264 (1993): 1425-31
  • Lee KL, Jim MH, Tang SC, Tai YT "QT prolongation and torsades de pointes associated with clarithromycin." Am J Med 104 (1998): 395-6
  • Choudhury L, Grais IM, Passman RS "Torsades de pointes due to drug interaction between disopyramide and clarithromycin." Heart Dis 1 (1999): 206-7
  • Gitler B, Berger LS, Buffa SD "Torsades de pointes induced by erythromycin." Chest 105 (1994): 368-72
Disopyramide

Generic Name: disopyramide

Brand name: Norpace, Norpace CR

Synonyms: n.a.

Zithromax (Azithromycin Oral Suspension)

Generic Name: azithromycin

Brand name: Zithromax, Zmax, AzaSite, Azithromycin 3 Day Dose Pack, Azithromycin 5 Day Dose Pack, Zithromax Tri-Pak, Zithromax Z-Pak, Zithromax IV

Synonyms: Zithromax

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.